SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is trending as investors react to reports that the airline has engaged advisors to explore potential M&A options, fueling speculation about a possible acquisition by a major carrier. Community discussion is heavily divided between bullish sentiment regarding a potential buyout premium and bearish concerns over the company's significant debt load, ongoing profitability challenges, and the potential for regulatory hurdles.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is capturing significant community attention as investors debate its long-term potential versus recent price volatility, with many users actively accumulating and staking the asset on dips. Discussion remains heavily focused on the network's high transaction speeds, utility through payment integrations, and the ongoing growth of its meme coin ecosystem.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle Mexican Grill remains a heavily debated stock among retail investors, with discussion split between those viewing the current valuation as a generational buying opportunity and others frustrated by perceived portion sizes and sluggish performance. Community focus remains pinned on the company's international expansion efforts and potential brand turnaround as investors compare its trajectory against competing fast-casual brands.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing significant volatility and rotation, as investors weigh potential M&A catalysts and clinical readouts against broader macro-economic concerns, including rising bond yields and sector-wide regulatory scrutiny. The community remains focused on high-conviction clinical-stage assets, balancing enthusiasm for potential breakthroughs in oncology and metabolic disease against a cautious outlook regarding the broader economic climate impacting small-cap biotech valuations.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing intense market activity as investors weigh its aggressive expansion into the weight-loss peptide space against significant short interest. Community sentiment is deeply divided, with bulls pointing to positive analyst revisions and long-term telehealth growth, while bears emphasize historical volatility and skepticism around competitive pressures in the GLP-1 market.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining traction as investors react to the project's v4 launch and a revenue-sharing model that rewards node runners and stakers with earnings from its decentralized GPU compute network. Community sentiment is largely driven by a significant supply shock, as the majority of circulating tokens are locked in long-term staking, leaving a limited float that many speculators believe could amplify price moves as demand for AI infrastructure grows.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing heightened activity as the community remains deeply divided between long-term holders defending the original project and proponents of newer, alternative versions on the Base chain. Discussions are currently dominated by heated debates regarding token utility, persistent skepticism over market performance, and contrasting narratives about the future of meme-based assets.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne is trending as investors digest its inclusion in the Nasdaq-100, which is triggering forced institutional demand and structural rebalancing. The community is actively debating the company's long-term valuation compared to other AI infrastructure players while tracking its technical breakout patterns and role in the high-end semiconductor testing cycle.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is drawing significant investor attention due to its rapid fleet expansion and aggressive push into new verticals like hospital logistics and kitchen automation. The community remains intensely focused on the stock's high short interest and speculative squeeze potential, while weighing the company's ambitious revenue growth targets against ongoing cash burn concerns.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending as investors digest the recent strategic licensing of ervogastat from Pfizer to bolster its MASH pipeline. Community sentiment remains focused on the potential for long-term growth and persistent buyout speculation, though some participants are expressing caution regarding the company's high operating expenses and lack of explicit near-term profitability guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics Reports Improvements In Heart Drug Trial

Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.read more...

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Multiple clinical-stage companies are delivered meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. $NTHI, $SLBT, $CRVO, $EWTX

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., June 3, 2026 BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal

EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on...

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business PR Newswire SURESNES, France, June 1, 2026 Acquisition supportsServier's strategic ambition in rare neurology for patients with high unmet medical...

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on...

Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.47	--	--	N/A
Q1 '26	-$0.49	-$0.46	5.39%	BEAT
Q4 '25	-$0.43	-$0.47	-8.48%	MISSED
Q3 '25	-$0.40	-$0.39	1.86%	BEAT
Q2 '25	-$0.41	-$0.34	17.91%	BEAT

EWTXEdgewise Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest EWTX News